6307-67-1

Basic information

• Product Name: 2-chloro-N-(2-chloro-6-Methylphenyl)acetaMide
• Synonyms: 2-chloro-N-(2-chloro-6-Methylphenyl)acetaMide;2,2-Dichloro-6-methylacetanilide
• CAS NO: 6307-67-1
• Molecular Formula: C₉H₉Cl₂NO
• Molecular Weight: 218.07986
• Mol File: 6307-67-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 349.2°Cat760mmHg
• Flash Point: 165°C
• Appearance: /
• Density: 1.345g/cm³
• Vapor Pressure: 4.76E-05mmHg at 25°C
• Refractive Index: 1.595
• Storage Temp.: 2-8°C
• Solubility: Acetone, Dichloromethane
• CAS DataBase Reference: 2-chloro-N-(2-chloro-6-Methylphenyl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-(2-chloro-6-Methylphenyl)acetaMide(6307-67-1)
• EPA Substance Registry System: 2-chloro-N-(2-chloro-6-Methylphenyl)acetaMide(6307-67-1)

Safety Data

• Hazardous Substances Data: 6307-67-1(Hazardous Substances Data)

Usage

Description

2-chloro-N-(2-chloro-6-Methylphenyl)acetaMide, also known as 2,2''-Dichloro-6''-methylacetanilide, is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its chemical structure, which includes two chlorine atoms and a methyl group attached to an acetamide functional group.

Uses

Used in Pharmaceutical Industry:
2-chloro-N-(2-chloro-6-Methylphenyl)acetaMide is used as an intermediate in the synthesis of Butanilicaine Hydrochloride, a local anesthetic. It plays a vital role in the development of this anesthetic agent, which is used to numb specific areas of the body during medical procedures, providing pain relief and ensuring patient comfort.

InChI:InChI=1/C9H9Cl2NO/c1-6-3-2-4-7(11)9(6)12-8(13)5-10/h2-4H,5H2,1H3,(H,12,13)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 87-63-8 2-chloro-6-methylaniline 
• 79-07-2 Chloroacetamide 

Downstream Products

• 110060-25-8 piperidino-acetic acid-(2-chloro-6-methyl-anilide) 
• 102169-22-2 N-benzyl-N-butyl-glycine-(2-chloro-6-methyl-anilide) 
• 70289-10-0 N,N-dimethyl-glycine-(2-chloro-6-methyl-anilide) 
• 1236306-22-1 N-(2-chloro-6-methylphenyl)-2-(4-(4-(pyridin-4-ylmethyl)phthalazin-1-yl)piperazin-1-yl)acetamide 
• 1236306-35-6 N-(2-chloro-6-methylphenyl)-2-(4-(4-benzylphthalazin-1-yl)piperazin-1-yl)acetamide 
• 302964-08-5 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide 

Relevant articles and documents

Design and Synthesis of Novel Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors with the Ability to Rescue Auditory Gating Deficit in Mice

A series of novel thiazolo[4,5-d]pyrimidin-7(6H)-ones (3aa-3eq) were designed, synthesized, and evaluated as the type I positive allosteric modulators of human α7 nAChR expressed in Xenopus ooctyes by a two-electrode voltage clamp. The structure-activity relationship analysis identified the compound 3ea as a potent and efficacious PAM with the maximum activation effect of the α7 current of over 1633% in the presence of acetylcholine (100 μM) and an EC50 = 1.26 μM. It is highly specific to α7 nAChR over other subtypes of nAChR, 5-HT3A, NMDA, and GABAA receptors. Compound 3ea showed an elimination half-life of 10.8 ± 1.5 h for 3 mg/kg, i.v., and 7.4 ± 1.1 h for 60 mg/kg, i.g. in rat. It also exhibited sufficient blood-brain barrier penetration with no significant effect on hERG channel. Most importantly, compound 3ea dose-dependently (0.1-1 mg/kg, i.p.) reversed the prepulse inhibition deficit induced by MK-801 in the mouse schizophrenia model.

THIAZOLOPYRIMIDINONE COMPOUNDS AND PREPARATION METHODS AND USE THEREOF

The present invention provides structural details of a thiazolopyrimidinone compound, a preparation method thereof, and use thereof in the manufacture of a medicament for the treatment of central nervous system diseases.

Synthesis and biological activity of some 1,3-dihydro-2H-3-benzazepin-2- ones with a piperazine moiety as bradycardic agents

A series of 1,3-dihydro-2H-3-benzazepin-2-ones with a piperazine moiety were designed and synthesized by treating the common intermediate of 1,3-dihydro-7,8-dimethoxy-3-[3-(1-piperazinyl)-propyl]-2H-3-benzazepin-2-ones with a variety of N-aryl-2-chloroacetamides and acyl chlorides. Their structures have been characterized by 1H-NMR, MS, and elemental analysis. The title compounds were evaluated for their bradycardic activity in vitro. Most of the synthesized compounds exhibited some vasorelaxant activity and heart-rate-reducing activity with bradycardic potency.